

FOR IMMEDIATE RELEASE

Contact:
Byron Cheatham
334.737.3127
Byron.Cheatham@CytoViva.com

CYTOVIVA® OPTICAL TECHNOLOGY AWARDED PATENTS

Advancements in nano-technology and pathogen research occurring as a result of this new technology

Auburn, AL – February 2, 2010 – CytoViva® Inc., is a leading provider of optical microscopy and hyperspectral imaging technology to the nanotechnology and pathogen research market. Recently its proprietary optical illumination system was awarded multiple patents (U.S. patent numbers 7,542,203 and 7,564,623) based on both the application and apparatus configuration of the technology.

Providing a high signal to noise optical image, this unique illumination technology enables observation of a wide range of nano-scale materials as they interact with biologicals and with composite materials. In addition, pathogens, including bacteria and virus, can be visualized when these optics are integrated onto a research grade microscope.

CytoViva has combined this patented optical capability with a proprietary hyperspectral imaging configuration. This integrated hyperspectral microscope solution enables high resolution spectral quantification of samples in nano-drug delivery, nano-toxicology and other nano-technology related research initiatives. These combined technologies are also advancing certain initiatives in pathogenic-based research.

CytoViva systems are currently utilized in many of the leading research centers across the world. This includes research hospitals such as Johns Hopkins and MD Anderson in addition to government laboratories including the FDA, NASA and NIH. This technology has received wide acclaim, winning two R&D 100 awards and a Nano50™ award.

Further information may be obtained by calling CytoViva at (334) 737-3127 or by visiting the CytoViva web site at: www.cytoviva.com.